In the absence of trials, a post hoc analysis compared stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy (HDR-BT) in intermediate-risk prostate cancer.

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new, clinically validated genetic ...

A pooled analysis of five prospective trials showed that stereotactic body radiotherapy (SBRT) was associated with a lower risk for biochemical failure over 10 years vs high-dose rate brachytherapy ...

The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...

SBRT reduced biochemical failure and acute GU toxicity compared with HDR brachytherapy in intermediate-risk prostate cancer. Read more about the findings.

In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer.

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary therapies, and medication.

The 2026 European Association of Urology (EAU) annual meeting featured an advancements in metastatic castration resistant prostate cancer (mCRPC) therapy session and a presentation by Dr. Giulio ...

In a Phase 3 randomized trial, Mass General Brigham researchers found that stereotactic radiation targeting individual tumors led to lower symptom burden, better cognitive outcomes, and better day to ...